# Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

> **NCT00263874** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 324 (—)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** UK-500,001

## Key facts

- **NCT ID:** NCT00263874
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 324 (—)
- **Why stopped:** The decision to terminate was completely related to efficacy and there were no safety concerns.
- **Last updated:** 2007-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263874, "Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00263874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*